Barclays Maintains Overweight on Viatris, Raises Price Target to $25
Benzinga Newsdesk 17 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $22 to $25.
Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $22 to $25.
